Colorectal cancer

Indexed in Crossref

27 abstracts matching colorectal cancer from the meeting's journal supplement, fetched live from Crossref 2026-11-12 10:29 UTC. This is a keyword search, not the complete abstract book.

• 39
  Identification of novel markers of inflammation in advanced colorectal cancer (CRC) using soluble high-throughput proteomics

  Teresa Smit, Ronald Anderson, Helen C Steel, Theresa M Rossouw et al.
• 426
  Extending organ preservation beyond rectal cancer with neoadjuvant programmed death 1 blockade in mismatch repair deficient tumors

  Johnathan R Esrail
• 1097
  A modular patient-derived colorectal cancer platform with autologous TILs and CAFs for immunopharmacological drug discovery

  Mara Gilardi
• 1045
  Dual-antigen cancer vaccine co-targeting human PD-L1 and PRAME induces specific immune responses in hPD-1/hPD-L1/HLA-A2.1 mice and inhibits tumor growth in an HLA-A2.1/hPRAME mouse colon cancer model

  Kin-Tak Chan, Melvin Toh
• 1099
  TNF-α induced inflammatory signature in colorectal cancer inhibits NK cells through cancer associated fibroblast NECTIN2 signalling

  Lei Lei, Xiaoyue Hong, Norashikin Zakaria, Raheleh Amirkhah et al.
• 1105
  HER3 inhibition sensitizes metastatic colorectal and pancreatic cancer to immunotherapy

  Chao Wei, Moeez Rathore, Elizabeth Bryson, Kimberly Curry et al.
• 883
  A novel CDH17/HER3 bispecific ADC demonstrates superior preclinical efficacy in colorectal cancer

  Xueyuan Jiang, Zeliang Guan, Yiqing Hu, Yuelei Shen et al.
• 781
  Rewiring immunity as steroid receptor coactivator-3 knockout turns Tregs against colorectal cancer

  Eunsu Kim, Nuri Sung, Jun Pill Won, David Lonard et al.
• 1137
  Spatial transcriptomics meta-analysis identifies local immune programs across primary colorectal cancer and liver metastases

  Othmane Jadi, Reuben R Cano, Jatin Roper, Nicholas C DeVito
• 465
  Real-world outcomes of first-line pembrolizumab in MSI-H/dMMR metastatic colorectal cancer: a single-centre audit

  Muhammad K S Niazi, Shiyam Kumar, Imran Hassan, Sarah Qasim
• 256
  In vivo generation of GUCY2C-targeting CAR T cells via a surface-engineered lentiviral vector for colorectal cancer therapy

  Chichun Yang, Jia Fu, Feng Zhang, Haihua Gu
• 1133
  High-resolution spatial transcriptomics identifies age-associated immune–stromal niches in advanced colorectal cancer

  Jess Hatfield, Andrei Tong, Jennifer L Modliszewski, Emily Merritt et al.
• 1132
  Spatial mapping and significance of the IL-12 pathway in human colorectal cancer

  Juan Guiza Higuera, Lucy Zheng, Luciene Borges, Sandra Martinez-Morilla et al.
• 903
  A novel CDH17-targeting CD3xCD28 trispecific T-cell engager demonstrates potent anti-tumor activity against colorectal cancer in preclinical models

  Liu Yang, Baihong Liu, Xueyuan Jiang, Xue Li et al.
• 118
  LAT1 (SLC7A5) expression shapes the colorectal cancer tumor immunemicroenvironment and independently predicts time to next treatment

  Kelly Pum, Emil Lou, Subbaya Subramanian, Justin Hwang et al.
• 463
  Evaluation of intravenous IPI201 in combination with anti-PD-1 therapy in a colorectal cancer mouse model

  Brett J Lanier, Deborah Mosca, Herbert Neuman, Robert B Stein et al.
• 739
  In vitro therapeutic strategies in MSI-H colorectal cancer organoid–immune cell co-culture systems

  Mahshid Mohammadi, Nityanand Srivastava, Muzaffer Ahmed Bhat, Ning Wei et al.
• 381
  Tumor DNA-loaded extracellular vesicles activate CD8 s T cells cGAS-STING signaling to overcome PD-1 resistance in MMR-proficient colorectal cancer

  Yeji Lee, Minjeong Kwon, Gi-Hoon Nam, In-San Kim
• 1182
  Safety and preliminary antitumor activity of the oral ENPP1 inhibitor, vizenpistat, combined with botensilimab and balstilimab in refractory metastatic microsatellite stable colorectal cancer

  Alexis Weston, Mohan R Kaadige, Trason Thode, Margaux Steinbach et al.
• 518
  Phase I study of SAR445877 in combination with FOLFOX6 and bevacizumab as first-line treatment for microsatellite stable metastatic colorectal cancer (MSS-CRC)

  Maria Pia Morelli, Mohamed H Derbala, Bettzy Stephen, Sherif Ismail et al.
• 520
  Spatial profiling and clinical outcomes of nelmastobart, a first-in-class anti-BTN1A1 antibody, with trifluridine/tipiracil and bevacizumab in refractory colorectal cancer (STCUBE-003)

  Stephen S Yoo, Soohyeon Lee, Sae Won Han, Keun-Wook Lee et al.
• 1149
  Integrating spatial profiles and cancer genomics to identify immune-infiltrated mismatch repair proficient colorectal cancers

  Jeremiah Wala, Kristin Qian, Yi Lu, Clarence Yapp et al.
• 653
  Dual PD-1 and CTLA-4 blockade enhances durable tumor control following BRAF and EGFR inhibition in a syngeneic BRAF V600E colorectal cancer model

  Irfan Naseem Bandey, Alexey Sorokin, Preeti K Marie, Jay Saynonh et al.
• 270
  AgenT-797, an allogeneic iNKT cell therapy, enables tumor-cell killing in a human organoid model of immune checkpoint inhibitor–refractory colorectal cancer liver metastases

  Shanmugarajan Krishnan, Bishnu Joshi, Justin G Keith, Olivier Le Tonqueze et al.
• 226
  Development of AB-7000, a logic-gated CAR T cell therapy intended for the treatment of metastatic colorectal cancer

  Irene Scarfo, Tiffany Chien, Rakesh Sudhakar, Xinyan Tang et al.
• 700
  Peritoneal fluid monocytes replenish a LYVE1 + tumor-border macrophage niche that restricts CD8 + T cell infiltration and function in colorectal cancer peritoneal metastasis

  Jichang Han, Shuai Gao, Ashlee Seldomridge, Alexandre Gallerand et al.
• 472
  Clinical features of long-term survivors treated with next-generation anti–CTLA-4 (botensilimab) plus anti–PD-1 (balstilimab) in refractory microsatellite-stable metastatic colorectal cancer

  Anthony B El-Khoueiry, Andrea J Bullock, Marwan G Fakih, Apostolia M Tsimberidou et al.